Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Clearside Biomedical, Inc. (CLSD) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/14/2023 8-K Quarterly results
Docs: "Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update - Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Progressing as Planned with Nearly 30 Sites Now Open - - Proprietary Suprachoroidal Injection Platform Featured in Peer-Reviewed Publication and at ARVO, ASRS and OIS Scientific Meetings - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., August 14, 2023 -- Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space , today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “The last several months have been very productive for Clearside with the initiation..."
05/11/2023 8-K Quarterly results
Docs: "Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update - Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected to Open Enrollment in Q2 2023 - - Positive Safety Data, Duration and Biologic Effect of CLS-AX Over 6 Months in OASIS Phase 1/2a Extension Study Highlighted in Presentations at Recent Medical Meetings - - Management to Host Webcast and Conference Call Today at 8:30 A.M. ET - ALPHARETTA, Ga., May 11, 2023 -- Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space , today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “We have delivered a productive start to 2023 as we continue exec..."
04/18/2023 8-K Quarterly results
03/09/2023 8-K Quarterly results
Docs: "Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update - Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Q2 2023 - - Medical Meeting Presentations Highlight Significant Potential of CLS-AX Based on Positive OASIS Phase 1/2a Safety Data, Durability, and Biologic Effect Over 6 Months - - Continued Growth in Retinal Specialists Trained in Suprachoroidal Space Injection Procedure Using FDA-Approved XIPERE® - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., March 9, 2023 -- Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space , today reported financial results for the fourth ..."
02/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/02/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...
Docs: "Presentation",
"Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX in Wet AMD - Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders - - 67% of Extension Study Participants Went at Least 6 Months Without Needing Additional Treatment - - Extension Participants Experienced a 77 - 85% Reduction in Treatment Burden Over 6 Months - - Webcast and Conference Call Today at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Mark R. Barakat, M.D. - ALPHARETTA, Ga., February 2, 2023 - Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space , annou..."
11/09/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
06/23/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
03/10/2022 8-K Quarterly results
Docs: "Three Months Ended December 31, Year Ended December 31, 2021 2020 2021 2020 License and other revenue $ 25,687 $ 11 $ 29,575 $ 7,894 Operating expenses: Research and development 3,840 4,472 18,537 15,073 General and administrative 3,140 2,649 11,665 10,756 Total operating expenses 6,980 7,121 30,202 25,829 Income from operations 18,707 Other income 2 ̶— 1,003 — Other expense — — Net income $ 18,709 $ $ 376 $ Net income per share of common stock — basic and diluted $ 0.31 $ $ 0.01 $ Weighted average shares outstanding — basic 59,669,759 49,048,402 58,491,986 46,506,540 Weighted average shares outstanding — diluted 61,182,414 49,048,402 59,906,602 46,506,540 Balance Sheet Data December 31, December 31, 2021 2020 Cash and cash equivalents $ 30,436 $ 17,287 Accounts receivable 10,000 — ..."
03/03/2022 8-K Quarterly results
12/21/2021 8-K Investor presentation
Docs: "AMD TRIAL DESIGN AND OBJECTIVES",
"Source: Clearside Biomedical, Inc."
11/10/2021 8-K Quarterly results
Docs: "Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 License and other revenue $ 3,074 $ 3,432 $ 3,888 $ 7,883 Operating expenses: Research and development 5,147 3,490 14,697 10,601 General and administrative 2,816 2,374 8,525 8,107 Total operating expenses 7,963 5,864 23,222 18,708 Loss from operations Other income 2 ̶— 1,001 — Other expense — — Net loss $ $ $ $ Net loss per share of common stock — basic and diluted $ $ $ $ Weighted average shares outstanding — basic and diluted 59,474,346 46,976,649 58,095,080 45,653,068 Balance Sheet Data September 30, December 31, 2021 2020 Cash and cash equivalents $ 25,217 $ 17,287 Total assets 27,378 19,322 Deferred revenue 5,000 5,000 Long-term debt — 991 Total liabilities 9,530 10,559 Total stockholders’ equ..."
10/25/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BAUSCH + LOMB AND CLEARSIDE BIOMEDICAL ANNOUNCE FDA APPROVAL OF XIPERE™ FOR SUPRACHOROIDAL USE FOR THE TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS XIPERE™ is the First and Only Medicine to be Approved in the United States for Delivery via Suprachoroidal Injection, a Method Designed to Facilitate Targeted Delivery of Therapeutic Agents to the Retina and Choroid LAVAL, Quebec, and ALPHARETTA, Ga., Oct. 25, 2021 – Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. , and Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space , today announced that the U.S. Food and Drug Administration has approved XIPERE™ for suprachoroidal use for the treatment of macular..."
08/10/2021 8-K Quarterly results
Docs: "Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 License and other revenue $ 780 $ 354 $ 814 $ 4,451 Operating expenses: Research and development 4,060 3,300 9,550 7,111 General and administrative 2,816 2,611 5,709 5,733 Total operating expenses 6,876 5,911 15,259 12,844 Loss from operations Other income 1 — 999 — Other expense — — Net loss $ $ $ $ Net loss per share of common stock — basic and diluted $ $ $ $ Weighted average shares outstanding — basic and diluted 57,745,465 45,214,500 57,394,017 44,984,005 Balance Sheet Data June 30, December 31, 2021 2020 Cash and cash equivalents $ 26,414 $ 17,287 Total assets 28,592 19,322 Deferred revenue 5,000 5,000 Long-term debt — 991 Total liabilities 9,254 10,559 Total stockholders’ equity 19,338 8,763 Source: Clearsid..."
06/15/2021 8-K Quarterly results
06/10/2021 8-K Quarterly results
06/04/2021 8-K Quarterly results
05/17/2021 8-K Quarterly results
03/10/2021 8-K Quarterly results
01/08/2021 8-K Quarterly results
01/05/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "CLEARSIDE BIOMEDICAL, INC."
08/10/2020 8-K Quarterly results
06/18/2020 8-K Quarterly results
05/08/2020 8-K Quarterly results
04/28/2020 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Other Ev...
Docs: "Clearside Biomedical Revises NDA Resubmission Timeline and XIPERE™ Commercial Partnership with Bausch Health - Management to Host Webcast and Conference Call Today at 8:30 A.M. ET -"
04/22/2020 8-K Appointed a new director
Docs: "Clearside Biomedical Appoints Nancy J. Hutson, Ph.D. to its Board of Directors - Pfizer veteran brings global R&D expertise to Board of Directors -"
04/08/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Corporate Presentation"
03/16/2020 8-K Quarterly results
03/13/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy